NCT05289076 2023-12-01
CRLM-Z
University Hospital, Linkoeping
Phase 1/2 Unknown
Clinical Trials
29 trialsNCT05506566 2023-09-21
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Unknown
NCT05515783 2023-09-21
68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Unknown
NCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT05268666 2023-06-15
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Jubilant Therapeutics Inc.
Phase 1/2 Unknown
NCT05834231 2023-04-28
Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity
Mansoura University
Phase 1/2 Unknown
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT04614740 2022-12-13
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
Jiangsu vcare pharmaceutical technology co., LTD
Phase 1/2 Unknown
NCT04640246 2022-02-02
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
Taiga Biotechnologies, Inc.
Phase 1/2 Unknown
NCT04652206 2021-12-29
PANTAX-Ib
Scandion Oncology A/S
Phase 1/2 Unknown
NCT04536454 2021-05-11
SenPET
University Hospital Tuebingen
Phase 1/2 Unknown
NCT04386343 2020-08-24
CH1701
Vietlife Healthcare Corporation
Phase 1/2 Unknown
NCT04085159 2020-06-12
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT04202601 2019-12-19
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
Peking University
Phase 1/2 Unknown
NCT03535246 2019-09-19
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03931720 2019-04-30
Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
Asclepius Technology Company Group (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT03792724 2019-01-03
INTRUST
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown
NCT03765190 2018-12-05
PI-MMC
Peking University First Hospital
Phase 1/2 Unknown
NCT03636685 2018-08-17
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
ChineseAMS
Phase 1/2 Unknown
NCT03614650 2018-08-03
Immunotherapy Treating GI Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03058809 2018-05-31
Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood
Viatar LLC
Phase 1/2 Unknown
NCT02863471 2017-10-31
PanHIPEC
University Hospital Tuebingen
Phase 1/2 Unknown
NCT02901145 2016-09-15
Nivolumab in Relapsed Pediatric Solid Tumors
Hadassah Medical Organization
Phase 1/2 Unknown
NCT02822053 2016-07-04
Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms
First Affiliated Hospital of Zhejiang University
Phase 1/2 Unknown
NCT02822066 2016-07-04
Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas
First Affiliated Hospital of Zhejiang University
Phase 1/2 Unknown
NCT02263950 2015-09-07
LON002-002
LondonPharma Ltd.
Phase 1/2 Unknown
NCT01760811 2013-01-04
CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT
Rabin Medical Center
Phase 1/2 Unknown
NCT00726687 2012-07-19
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
Alaunos Therapeutics
Phase 1/2 Unknown
NCT00214838 2006-12-05
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
Callisto Pharmaceuticals
Phase 1/2 Unknown